Infections and cancer
PRINCIPAL INVESTIGATORS
- Francesc Xavier Bosch José
- Raquel Ibáñez Pérez
- Laura Costas Caudet
- Sònia Paytubi Casabona
- Mireia Díaz Sanchís
- Laia-Valeria Bruni Coccoz
- Claudia Robles Hellin
- Miguel Angel Pavon Ribas
- Maria Brotons Agulló
- Delphine Casabonne
CLINICAL RESEARCHERS
- Samuel Perez Carton
- Maria Eulalia Fernandez Montoli
POSTDOCTORAL RESEARCHERS
- Ginesa Albero Abril
PREDOCTORAL RESEARCHERS
- Jon Frias Gomez
- Beatriz Serrano Carro
- Sara Hermosa Garcia
- Maryam Choulli Amgait
- Paula Àngela Peremiquel Trillas
- Alvaro De Andres Pablo
SCIENTIFIC SUPPORT
- Carlos Javier Dommar D Lima
- Ainhoa Botella Cayuelas
- Victoria Lopez Codony
- Maria Del Pilar Vidaurre Teixidó
- Beatriz Quirós Blasco
- Yolanda Florencia Melgarejo
- Francisca Morey Cortes
- Vanesa Camon Melguizo
- Alexandra Montoliu Gimenez
- Sara Tous Belmonte
- Laura Monfil Herrera
- Laura Asensio Puig
- Alexandre Armillas Montornes
- Esther Roura Fornells
- Ana Esteban Miró
- David Gómez Guillén
- Claudia Pavon Diaz
- Marleny Vergara Muñoz
- Yolanda Benavente Moreno
- Irene Onieva Hernandez
- Victoria Porthe
- Antonio Sanchez Baos
- Beatriz Thais Pelegrina Sanchez-Dehesa
- Omar Clavero Carletti
- Valentina Rangel Sarmiento
MANAGEMENT SUPPORT
- Francisco Javier Ruiz Carrasco
- Marta Lopez Querol
- Olga Romero Clara
- Frederic Rodilla Pamies
- Natividad Paton Morales
- Jesus Muñoz Villanueva
- Maria Gema Carretero Garcia
- Diana Salinas Hidalgo
- Mireia Montserrat Moreno
- Arnau Guasch Girbau
- Gaetano Vaggione
Cancer
EPIBELL
Scientific production
30
PAPERS
Average IF: 4,60
16
LED PAPERS
Average IF: 4,09
4 PUBLICATIONS IN FIRST DECILE
22 PUBLICATIONS IN FIRST QUARTILE
26 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Thakral,A;Lee,JJW;Hou,TZC;Hueniken,K;Dudding,T;Gormley,M;Virani,S et al, Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study, Nat Commun, 2024;15(1):doi:10.1038/s41467-024-51679-x
- Costas,L;Frias Gomez,J;Peinado,FM;Molina,JM;Peremiquel Trillas,P;Paytubi,S;Crous Bou,M et al, Total Effective Xenoestrogen Burden in Serum Samples and Risk of Endometrial Cancer in the Spanish Screenwide Case-Control Study, Environ Health Perspect, 2024;132(2):27012-27012, doi:10.1289/EHP13202
- Peeri,NC;Bertrand,KA;Na,RH;De Vivo,I;Setiawan,VW;Seshan,VE;Alemany,L et al, Understanding risk factors for endometrial cancer in young women, JNCI-J. Natl. Cancer Inst., 2024;117(1):76-88, doi:10.1093/jnci/djae210
- von Buchwald,C;Jakobsen,KK;Carlander,A;Tous,S;Gronhoj,C;Rasmussen,JH;Brooks,J et al, TNM 8 staging system beyond p16: Double HPV/p16 status is superior to p16 alone in predicting outcome in oropharyngeal squamous cell carcinoma, Eur J Cancer, 2024;211114329-114329, doi:10.1016/j.ejca.2024.114329
- Fernandez Deaza,G;Serrano,B;Roura,E;Castillo,JS;Caicedo Martinez,M;Bruni,L;Murilloa,R, Cervical cancer screening coverage in the Americas region: a synthetic analysis, Lancet Regional Health-Americas, 2024;30doi:10.1016/j.lana.2024.100689
Research highlights
PROJECTS
10 Granted competitive projects
24 Ongoing competitive projects
1 Started clinical trial
12 Ongoing clinical trials
1 Ongoing non-competitive project
PUBLISHED WORKS
1 Thesis
NETWORKS
AGAUR SGR GRC
CIBERESP
Selected projects
- 101155975. HPV-FASTER-Implement: Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study (101155975). COMISSIÓ EUROPEA. Budget: 597.531,25€. 2025-2029. PI: ROBLES HELLIN, CLAUDIA.
- 101075314. PERCH: PartnERship to Contrast HPV. COMISSIÓ EUROPEA. Budget: 409.468,03€. 2022-2025. PI: Brotons Agulló, Maria.
- GA 847845. RISCC: RISK-BASED SCREENING FOR CERVICAL CANCER. COMISSIÓ EUROPEA. Budget: 37.8125€. 2020-2024. PI: Bosch José, Francesc Xavier.
- CPP2021-008440. WOMEC ADVANCED : NUEVAS APROXIMACIONES PARA EL DIAGNÓSTICO DE CÁNCER DE ENDOMETRIO. Ministerio de Ciencia e Innovación. Budget: 194.288€. 2022-2025. PI: COSTAS CAUDET, LAURA.
- 2019-003236-23. ENSAYO CLÍNICO EN FASE 3, INTERNACIONAL, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA ESTUDIAR LA EFICACIA, LA INMUNOGENICIDAD Y LA SEGURIDAD DE LA VACUNA 9VVPH, UNA VACUNA POLIVALENTE DE PARTÍCULAS VIROIDES L1, EN LA PREVENCIÓN DE LA INFECCIÓN BUCAL PERSISTENTE POR LOS TIPOS 16, 18, 31, 33, 45, 52 O 58 DEL VPH EN VARONES ADULTOS DE 20 A 45 AÑOS DE EDAD. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 224.455€. 2020- . PI: Alemany Vilches, Maria Eulalia.